X-BODY Biosciences and SRU Biosystems announced a major collaborative advance in the application of the SRU BIND label-free protein detection platform for high-throughput label-free screening of high affinity antibodies. The two companies have developed and validated a novel BIND Biosensor design for use with the commercially available SRU BIND Reader that results in a >200-fold increase in sensitivity over SRU’s previous sensor. The novel biosensor allows for measurement of sub-nanomolar affinity interactions in an automated microplate format.
Commenting on the recent development, Dr Yan Chen, X-BODY’s vice president of antibody research, said, “For years, the therapeutic antibody community has sought a label-free, high throughput screening platform to accelerate the drug discovery process. This improved BIND protein detection system offers unprecedented throughput and sensitivity for antibody screening.”
The improved SRU BIND system allows for high affinity measurements in 384 or 1536 well microplate formats for diagnostic, manufacturing QC and drug discovery applications. X-BODY Biosciences has developed a novel platform for rapidly screening fully human antibody libraries that incorporates the improved SRU BIND Biosensor. X-BODY has validated the use of this new and improved SRU BIND system for drug discovery by employing the technology to rapidly identify and characterize therapeutic candidates.
X-BODY Biosciences was founded in 2008 by Richard Wagner, Gordon Binder, and Brant Binder. Dr Wagner previously co-developed the fibronectin domain antibody-mimetic platform at Phylos, later acquired by Bristol Myers Squibb, and the DirectSelect small molecule library screening system at Praecis Pharmaceuticals, acquired by GSK in 2007.
SRU Biosystems is a life science company developing novel technologies for rapidly analyzing the interactions of large genomic, protein, peptide, antibody or small molecule compound libraries against a wide range of biochemical and cellular targets.